Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1161]

UGN-102 shows better results after 12 months of treatment for low-grade...

Dr Sandip Prasad - Garden State Urology, Morristown, USA

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC ( Dr Sandip Prasad - Garden State Urology, Morristown, USA )

Mobile prostate cancer screening clinic can help address barriers to serving...

Dr Masood Moghul - The Royal Marsden Institute of Cancer Research, London, UK

Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities ( Dr Masood Moghul - The Royal Marsden Institute of Cancer Research, London, UK )

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in...

Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC ( Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA )

CaboNivo shows sustained long-term benefits for survival and tumour progression...

Prof Camillo Porta - University of Bari, Bari, Italy,

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta - University of Bari, Bari, Italy, )

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide...

Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone ( Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA )

Enfortumab vedotin in combination with pembrolizumab shows improved survival...

Prof Thomas Powles - Barts Cancer Institute, London, England

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC ( Prof Thomas Powles - Barts Cancer Institute, London, England )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Prostate cancer

Dr Alison Tree - Institute of Cancer Research, London, UK

Prostate cancer ( Dr Alison Tree - Institute of Cancer Research, London, UK )

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Pembrolizumab shows improvement in overall survival for clear cell renal cell...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar...

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona...

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Study shows association between tumour KIM-1 gene (HAVCR1) expression and...

Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece

Study shows association between tumour KIM-1 gene (HAVCR1) expression and immune infiltrates in RCC ( Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece )

More from ecancer